查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1801228

2025 年至 2033 年良性前列腺增生治療市場規模、佔有率、趨勢及預測（依治療類型及地區）

Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球良性前列腺增生治療市場規模達125億美元。展望未來， IMARC Group預測，到2033年，該市場規模將達到185億美元，2025-2033年期間的複合年成長率為4.4%。目前，北美佔據市場主導地位，2024年將佔據超過34.8%的市場。市場成長的驅動力包括老年男性良性前列腺增生（BPH）盛行率的上升、微創手術的進步以及藥物製劑的改進。雷射療法和聯合治療的創新進一步改善了患者的治療效果，從而增加了良性前列腺增生治療市場的佔有率。

良性攝護腺增生 (BPH) 治療市場的主要促進因素包括老年男性族群中 BPH 盛行率的上升、泌尿健康意識的增強以及微創治療方案的進步。由於 BPH 對生活品質（包括泌尿系統症狀和併發症）的影響，對有效療法的需求日益成長。包括雷射療法、改進的藥物配方和聯合用藥在內的創新也促進了市場的成長，同時，已開發地區醫療保健可及性的提高以及優惠的報銷政策也促進了市場的成長。例如，2024 年 9 月，皇家薩裡郡 NHS 基金會信託推出了 EchoLaser 治療良性前列腺增生，這種疾病影響著約 50% 的 50 歲以上男性。這項由前列腺計畫慈善機構資助的微創手術可快速恢復，副作用極小，進而改善患者的生活品質並減少住院時間。這些進步正在為良性前列腺增生治療市場創造一個積極的前景。

美國良性前列腺增生 (BPH) 治療市場的主要驅動力是老年男性群體中 BPH 的高盛行率以及人們對泌尿系統健康的認知不斷提高。雷射療法和前列腺動脈栓塞術等微創手術的進展也因其效率高和恢復時間短而廣受歡迎。例如，2023 年 7 月，波特蘭基督復臨安息日會推出了水消融療法 (Aquablation Therapy)，這是一種利用水和機器人精準治療良性前列腺增生 (BPH) 的微創療法。這種創新療法為男性治療攝護腺肥大症狀提供了新的選擇。此外，藥物和合併療法的改進也擴大了治療選擇的範圍。這進一步反映了美國良性前列腺增生治療市場的主要趨勢之一。

良性攝護腺增生治療市場趨勢：

轉向微創手術

微創手術在良性前列腺增生的治療中正日益普及。根據美國國立衛生研究院 (NIH) 的數據，估計約有 30% 的中度至重度前列腺增生 (BPH) 症狀男性會接受某種形式的微創治療。這些技術包括雷射治療、經尿道攝護腺切除術 (TUMT) 和經尿道攝護腺切除術 (TURP)。這些技術已被證實有效且恢復時間短，因此深受患者和醫生的青睞。這些手術確保治療精準，對周圍組織的損傷最小，從而減少出血或感染等併發症。此外，與傳統的開放性手術相比，患者疼痛減輕，恢復正常活動的速度也更快。這與醫療保健行業向微創門診服務發展的整體趨勢相契合。钬雷射剜除術和綠光雷射治療等技術的蓬勃發展進一步推動了市場的變革，如今，對於那些不願長期住院或接受侵入性手術的患者來說，他們可以選擇其他治療方案。隨著這些手術的接受度不斷提高，對良性攝護腺增生治療市場的需求也將逐漸增加。

先進藥物療法的出現

隨著新型藥物療法的出現，良性前列腺增生 (BPH) 的治療模式正在發生翻天覆地的變化。新型藥物和聯合療法旨在更好地控制症狀並減少副作用。根據美國國家糖尿病、消化和腎臟疾病研究所 (NIDDK) 的數據，51 至 60 歲男性中近 50% 患有良性前列腺增生 (BPH)，80 歲以上男性中高達 90% 患有 BPH，因此對藥物治療方案的需求日益成長。雖然 α 受體阻斷劑和 5-α 還原酶抑制劑等傳統療法仍在發揮作用，但 α 受體阻斷劑和 5-ARI 等先進藥物療法雖然是常用療法，但也伴隨著明顯的副作用，例如頭暈和性功能障礙。阿伏達特 (Avodart) 和西力士 (Cialis) 等藥物的專利到期為學名藥帶來了機遇，它們提供了價格合理的替代品，並推動了藥物治療市場的成長。諸如PDE5抑制劑和新型雙標靶療法等藥物的研發力度正在加大，它們為緩解症狀提供了更全面的方案。這些先進的藥物不僅可以治療前列腺，還可以治療勃起功能障礙－良性前列腺增生（BPH）的常見合併症。隨著治療方法的增多，這些患者可以享受個人化的、基於症狀的治療方案，從而更適合自己的健康狀況和症狀。另一個值得關注的趨勢是將現有藥物合併使用，以提高療效並最大限度地減少副作用。隨著生物製劑和基因療法進入臨床試驗階段，BPH的治療模式將發生更顯著的變化，為患者提供有效的長期治療。

老年人口不斷增加

全球老年人口是良性前列腺增生 (BPH) 治療市場的主要成長動力。隨著年齡成長，BPH 的發生率不斷上升，且在 50 歲以上的男性中最為常見。從 1974 年到 2024 年，全球 65 歲人口比例幾乎加倍，從 5.5% 上升到 10.3%。根據聯合國人口統計數據，從 2024 年到 2074 年，這一數字預計將再次加倍，達到 20.7%。同時，預計 80 歲及以上老年人口將超過目前的三倍。已開發地區的老年人口預計將大幅增加，從而顯著擴大需要 BPH 治療的人。這種人口結構變化可能會進一步加重醫療保健系統的壓力，因為它需要有效且價格合理的治療干預措施。全球人口老化正在刺激對 BPH 治療的需求，而學名藥提供了低成本的選擇，從而增加了患者的可及性和整體治療銷售。老年男性更容易患高血壓和糖尿病等併發症。這些併發症進一步加劇了良性前列腺增生 (BPH) 的治療難度，因此催生了客製化治療方案的需求，旨在同時滿足多種健康需求。老年人更容易受到 BPH 治療副作用的影響，例如頭暈和跌倒風險增加。隨著人口老化，透過更安全的治療方案最大限度地降低這些風險正成為醫療保健領域的首要任務。因此，製藥和醫療保健公司一直在開發治療 BPH 症狀的藥物，以全面提升患者（尤其是老年人）的生活品質。預計老齡化人口將繼續成長，並透過增加對藥物和手術治療方案的需求來影響市場。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球良性前列腺增生治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依治療類型

  • 藥物類別
    • 主要類型
      • 阿爾法受體阻斷劑
      • 5-α還原酶抑制劑（5-ARI）
      • 磷酸二酯酶-5酶抑制劑
      • 其他
  • 微創手術
    • 主要類型
      • 經尿道攝護腺切除術（TURP）
      • 經尿道攝護腺切開術（TUIP）
      • 經尿道微波熱療（TUMT）
      • 機器人手術
      • 前列腺尿道抬高術
      • 其他
  • 雷射治療
  • 其他

第7章：市場區隔：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 8 章：SWOT 分析

第9章：價值鏈分析

第 10 章：波特五力分析

第 11 章：價格分析

第 12 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Allergan plc (AbbVie Inc.)
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Boehringer Ingelheim GmbH (CH Boehringer Sohn AG & Ko. KG)
    • Boston Scientific Corporation
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2898

The global benign prostatic hyperplasia treatment market size was valued at USD 12.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 18.5 Billion by 2033, exhibiting a CAGR of 4.4% during 2025-2033. North America currently dominates the market, holding a significant share of over 34.8% in 2024. The market is driven by the rising prevalence of BPH among aging men, advancements in minimally invasive procedures, and improved drug formulations. Innovations in laser therapies and combination treatments further enhance patient outcomes, increasing the benign prostatic hyperplasia treatment market share.

Key drivers in the benign prostatic hyperplasia (BPH) treatment market are the increasing prevalence of BPH among the aging male population, increasing awareness of urological health, and advances in minimally invasive treatment options. The demand for effective therapies is growing due to the impact of BPH on quality of life including urinary symptoms and complications. Innovations including laser therapy improved drug formulation and combinations also enhance growth in the market along with a rise in healthcare access as well as favorable reimbursement policies in developed regions. For instance, in September 2024, Royal Surrey NHS Foundation Trust introduced EchoLaser treatment for benign prostate enlargement a condition affecting about 50% of men over 50. Funded by the Prostate Project charity, this minimally invasive procedure allows rapid recovery and minimal side effects improving patient quality of life and reducing hospital stays. These advancements are creating a positive benign prostatic hyperplasia treatment market outlook.

The key drivers of the United States benign prostatic hyperplasia (BPH) treatment market are a high prevalence of BPH among the aging male population and increased awareness of urological health. Advances in minimally invasive procedures such as laser-based therapies and prostatic artery embolization also gained popularity based on their efficiency and quicker recovery times. For instance, in July 2023, Adventist Health Portland launched Aquablation Therapy a minimally invasive treatment for benign prostatic hyperplasia (BPH) using water and robotic precision. This innovative procedure represents a new option for men dealing with enlarged prostate symptoms. There is also availability of improved medications and combination therapies which boost the range of treatment options. This further represents one of the key benign prostatic hyperplasia treatment market trends in the United States.

Benign Prostatic Hyperplasia Treatment Market Trends:

Shift Toward Minimally Invasive Procedures

Minimally invasive procedures are being increasingly used for the treatment of benign prostatic hyperplasia. According to the U.S. National Institutes of Health (NIH), an estimated 30% of men with moderate to severe BPH symptoms undergo some form of minimally invasive treatment. Techniques include laser therapy, TUMT, and TURP. These are well accepted by both patients and physicians because they have been proven effective with minimal recovery time. Such procedures ensure the treatment is targeted with minimal damage to the surrounding tissues and, therefore, fewer complications in the form of bleeding or infection. In addition, the patients face less pain and faster return to regular activities than the traditional open surgeries. This is in tune with the general trends in the healthcare sector toward less invasive outpatient-focused services. Growth of technologies like Holmium laser enucleation and GreenLight laser therapy further fueled the shifting market, to the extent that, nowadays, alternatives are offered to the patients who do not want to undergo long durations of hospitalization or an invasive surgery. The growing acceptance of these procedures will lead to increased benign prostatic hyperplasia treatment market demand over the time.

Emergence of Advanced Drug Therapies

The landscape of BPH treatment is undergoing a sea change with the emergence of new pharmacological therapies. New classes of drugs and combination therapies aim at better symptom management with fewer side effects. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 50% of men aged 51 to 60, and up to 90% of men over the age of 80, are affected by BPH, leading to a growing need for pharmacological treatment options. While traditional therapies like alpha-blockers and 5-alpha-reductase inhibitors continue to play their role, advanced drug therapies, such as alpha-blockers and 5-ARIs, are common treatments but come with notable side effects like dizziness and sexual dysfunction. The expiration of patents for drugs like Avodart and Cialis has opened opportunities for generics, providing affordable alternatives and driving market growth in drug treatments. Efforts are increasing to develop drugs like PDE5 inhibitors and novel dual-target therapies offer a more holistic approach to symptom relief. These advanced drugs treat not only the prostate but also erectile dysfunction, a common comorbidity for BPH. With more treatments available, these patients can take advantage of an individualized, symptom-based plan that is better suited to his or her health conditions and symptoms. Yet another trend to be seen includes combining existing medicines to improve potency and minimize harmful side effects. The landscape for BPH is set to change even more dramatically with the entry of biologics and gene therapies into clinical trials, providing the patient with effective long-term treatment.

Rising Geriatric Population

The global geriatric population is a major growth driver for the BPH treatment market. As people age, the incidence of BPH increases, and the condition is most common in men over the age of 50. From 1974 to 2024, the global proportion of individuals aged 65 nearly doubled, rising from 5.5% to 10.3%. From 2024 to 2074, the figure is set to double once more, reaching 20.7%, as per United Nations demographic estimates. At the same time, the population of individuals aged 80 and older is expected to exceed three times its current size. The elderly population is expected to increase substantially in developed regions, thus significantly expanding the pool of people requiring treatment for BPH. This demographic change is likely to further stress healthcare systems by demanding effective yet affordable treatment interventions. An aging global population is fueling demand for BPH treatments, with generics offering lower-cost options that increase patient access and overall treatment sales. Older males are more predisposed to co-morbidities like hypertension and diabetes. Such comorbidities further complicate the management of BPH, thus resulting in a driving force for tailormade regimens that meet multiple health demands at one time. Older adults are more vulnerable to side effects from BPH treatments, including dizziness and an increased risk of falls. With an aging population, minimizing these risks through safer treatments is becoming a priority in healthcare. Pharmaceutical and healthcare companies, therefore, have been developing drugs that treat the symptoms of BPH and generally enhance the quality of life for patients, especially the elderly. The aging population is projected to continue increasing and influence the market by enhancing the demand for pharmacological as well as surgical treatment options.

Benign Prostatic Hyperplasia Treatment Industry Segmentation:

Analysis by Treatment Type:

  • Drug Class
    • Alpha-Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally Invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Transurethral Microwave Thermotherapy (TUMT)
    • Robotic Surgeries
    • Prostatic Urethral Lifts
    • Others
  • Laser Therapy
  • Others

Alpha-blockers account for the highest market benign prostatic hyperplasia treatment market share of the drug class category in BPH treatment. They are potent in offering symptomatic relief as quickly as possible. They are able to relax the muscles within the prostate and bladder neck to facilitate urine flow and reduce obstruction. Alpha-blockers are first-line drugs used for BPH due to their efficacy, availability and fewer side effects. Their ability to treat lower urinary tract symptoms without significantly altering prostate size makes them highly preferred by physicians. Increasing awareness, a growing aging male population and advancements in drug formulations further bolster the dominance of alpha-blockers in the BPH treatment market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 34.8%. North America is the most significant market of BPH treatments mainly driven by the sophisticated healthcare infrastructure within the region and the high incidence of BPH among aging males along with better awareness about urological health. The United States is a notable contributor to the market due to its large population of geriatrics and the use of advanced medical treatments which include minimally invasive procedures as well as newer drug therapies. Favorable reimbursement policies along with cutting-edge technologies like robotic-assisted surgeries and laser therapies continue to support benign prostatic hyperplasia treatment market growth. The key pharmaceutical and medical device manufacturers located in the region also stimulate continuous innovation. The growing importance of early diagnosis and proactive management of BPH symptoms further enhance North America's position as a global leader in the BPH treatment market.

Key Regional Takeaways:

United States Benign Prostatic Hyperplasia Treatment Market

In 2024, the United States captured 85.00% of revenue in the North American market. The U.S. BPH market is increasing due to a growing aging male population and the rising awareness of treatment options. According to the American Urological Association, about 50% of men over 50 years old have BPH or an enlarged prostate. Prevalence of BPH rises with age and, among men aged 60 to 69 years, it reaches 70% and among those over 70 years, 80%. Growth drivers are major effective medical therapies like 5-alpha reductase inhibitors and alpha blockers along with increasing surgical procedure adoption. Market growth is further facilitated by a shift towards telemedicine and home-based treatments that ensure broader accessibility to care. This market is, therefore attracting more prominent players like AbbVie and Astellas into their portfolios by focusing on innovation and patient-centric approaches.

Europe Benign Prostatic Hyperplasia Treatment Market

The BPH market in the region is rapidly growing due to an aging population and the increasing prevalence of prostate enlargement. The European Association of Urology states that benign prostatic hyperplasia, or BPH, affects 50% of men over the age of 50, while the condition progresses with age and reaches 70% in the age group 60 to 69 and 80% above 70. The awareness about BPH symptoms and the high number of new diagnoses are main drivers for this market growth. In Germany, the UK, and France, among others, they are widely accepting advanced treatments with surgical minimally invasive approaches, drug therapies, and combination therapies where better management could be achieved for patients. Boehringer Ingelheim and Janssen, the two leading pharmaceutical giants, lead in innovating by introducing new drug formulations that meet unmet needs in BPH care. Additionally, telehealth solutions are picking up the pace in offering consultation and allowing for an early diagnosis that would be a driving factor in this European market growth.

Asia Pacific Benign Prostatic Hyperplasia Treatment Market

The Asia Pacific BPH market is growing rapidly because of the increasing awareness, aging male population, and improved access to healthcare. Asian Development Bank says, by 2050, one in four people in Asia and the Pacific will be over 60 years of age. Projections indicate that this demographic shift, where the population of older persons aged over 60 in the region is expected to triple from 2010 until 2050, will attain nearly 1.3 billion. This demographic shift will create a significant demand for BPH treatments as well, given the rising prevalence of BPH with age. According to an industry report, the market size for BPH was USD 1.8 billion in 2023 in this region, primarily driven by an escalating diagnosis rate and government initiatives to enhance the healthcare system in these countries. The main momentum-setters in this region are Japan, South Korea, and China, with the state-of-the-art advancements in BPH treatment technology, including robotic surgeries and novel pharmacological interventions. Herbal and traditional treatments are also gaining relevance more in the region, mainly in the Indian subcontinent.

Latin America Benign Prostatic Hyperplasia Treatment Market

Latin American BPH is experiencing a rising tide, mainly fueled by the rise in the population's aging demographic and the resultant increase in the need for effective treatment. According to the Pan American Health Organization (PAHO), 20% of men older than 50 years in this region suffer from BPH. In addition, there is a demand for BPH-related treatments within Brazil and Mexico. BPH progresses with age in a majority of Latin American male populations. Cancer of the prostate is the highest form of any cancer among male patients in Brazil and most cases, in fact, point to BPH. More recently, increased vigilance on symptomatic manifestations encourages men to search for treatments or even pharmaceutical-based and minimally invasive surgical treatments. Access to health care in Brazil and Mexico, for example, is expanding further, creating more room for market expansion. Local pharmaceutical firms and multinational players are also taking advantage of this trend to present a myriad of treatment options specific to the regional market.

Middle East and Africa Benign Prostatic Hyperplasia Treatment Market

The BPH market in the Middle East and Africa is set to grow based on the area's increasing aging population and growing attention to prostate care. According to the NIH, the prevalence rate of BPH in the Middle East ranges between 13.84% to 23.79%. In this regard, the variation was due to some demographic factors across the region in addition to differing access to care. As the male population aged above 50 continues to climb, BPH treatments remain in demand. Improving healthcare regimes in the form of better diagnosis rates are being recorded in Saudi Arabia and South Africa. Local players have scaled up their activities both on the medical and the surgical side, while international pharmaceutical majors have positioned themselves in the market. Increased attention on BPH management in both the public and private sectors is expected to spur major growth in the market over the next few years.

Competitive Landscape:

The benign prostatic hyperplasia (BPH) treatment market is highly competitive with numerous pharmaceutical and medical device companies offering a wide range of solutions from medications to minimally invasive procedures. Companies are focusing on innovation such as developing advanced drug formulations with improved efficacy and fewer side effects as well as refining minimally invasive techniques like laser therapies and robotic-assisted surgeries. The market is also seeing significant investment in clinical trials and the development of combination therapies to enhance treatment outcomes. Strategic partnerships, mergers and acquisitions are common enabling companies to expand their product portfolios and geographic reach.

The report provides a comprehensive analysis of the competitive landscape in the benign prostatic hyperplasia treatment market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Allergan Plc (AbbVie Inc.)
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
  • Boston Scientific Corporation
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the benign prostatic hyperplasia treatment market?
  • 2.What are the market drivers for benign prostatic hyperplasia (BHP) treatment devices?
  • 3.What is the benign prostatic hyperplasia (BPH) treatment device market growth?
  • 4.What are the key factors driving the benign prostatic hyperplasia treatment market?
  • 5.Which region accounts for the largest benign prostatic hyperplasia treatment market share?
  • 6.Which are the leading companies in the global benign prostatic hyperplasia treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Drug Class
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Alpha-Blockers
      • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
      • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Minimally Invasive Surgeries
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.4 Robotic Surgeries
      • 6.2.2.5 Prostatic Urethral Lifts
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast
  • 6.3 Laser Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Abbott Laboratories
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Allergan plc (AbbVie Inc.)
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
      • 12.3.2.4 SWOT Analysis
    • 12.3.3 Asahi Kasei Corporation
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
      • 12.3.3.4 SWOT Analysis
    • 12.3.4 Astellas Pharma Inc.
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
      • 12.3.4.4 SWOT Analysis
    • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 SWOT Analysis
    • 12.3.6 Boston Scientific Corporation
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 GlaxoSmithKline Plc
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
      • 12.3.7.3 Financials
      • 12.3.7.4 SWOT Analysis
    • 12.3.8 Pfizer Inc.
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
      • 12.3.8.4 SWOT Analysis
    • 12.3.9 Sanofi S.A.
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio
      • 12.3.9.3 Financials
      • 12.3.9.4 SWOT Analysis
    • 12.3.10 Teva Pharmaceutical Industries Ltd.
      • 12.3.10.1 Company Overview
      • 12.3.10.2 Product Portfolio
      • 12.3.10.3 Financials
      • 12.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2024
  • Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2024
  • Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2024
  • Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
  • Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
  • Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
  • Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players